CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Roche Holding AG (Participation) - ROGz CFD

250.5
0.99%
Market Trading Hours* (UTC) Opens on Tuesday at 07:00

Tue - Fri: 07:00 - 15:20

  • Summary
  • Historical Data
Trading сonditions
Spread 5.4
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.011438 %
Charges from full value of position ($-2.17)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.011438%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.010785 %
Charges from full value of position ($-2.05)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.010785%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.1
Currency CHF
Margin 5.00%
Stock exchange Switzerland
Commission on trade 0%

Key Stats
Prev. Close 253
Open 250.9
1-Year Change 13.63%
Day's Range 250.5 - 259.1
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 17, 2025 250.5 1.7 0.68% 248.8 260.8 248.1
Apr 16, 2025 253.0 1.6 0.64% 251.4 254.1 250.4
Apr 15, 2025 254.6 9.0 3.66% 245.6 255.1 245.6
Apr 14, 2025 246.3 -1.6 -0.65% 247.9 251.9 246.3
Apr 11, 2025 242.8 -2.0 -0.82% 244.8 245.7 238.1
Apr 10, 2025 237.5 -17.1 -6.72% 254.6 255.7 237.4
Apr 9, 2025 232.8 -1.0 -0.43% 233.8 241.9 231.5
Apr 8, 2025 251.3 1.2 0.48% 250.1 253.4 245.9
Apr 7, 2025 240.8 -6.8 -2.75% 247.6 256.7 240.8
Apr 4, 2025 260.7 -13.9 -5.06% 274.6 276.4 260.1
Apr 3, 2025 277.4 -3.8 -1.35% 281.2 282.5 274.8
Apr 2, 2025 285.5 -3.4 -1.18% 288.9 289.4 283.6
Apr 1, 2025 291.0 -1.3 -0.44% 292.3 294.9 289.8
Mar 31, 2025 286.1 -7.1 -2.42% 293.2 294.8 286.1
Mar 28, 2025 293.8 1.3 0.44% 292.5 296.6 291.8
Mar 27, 2025 293.2 0.1 0.03% 293.1 294.6 291.2
Mar 26, 2025 302.1 -2.4 -0.79% 304.5 304.7 300.3
Mar 25, 2025 304.7 0.2 0.07% 304.5 308.2 300.0
Mar 24, 2025 298.9 -8.4 -2.73% 307.3 308.0 298.8
Mar 21, 2025 307.7 2.8 0.92% 304.9 309.0 304.8

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Roche Company profile

About Roche Holding AG

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Roche Holding AG revenues increased 8% to SF62.8B. Net income decreased 3% to SF13.93B. Revenues reflect Diagnostics segment increase of 29% to SF17.76B, Chugai segment increase of 20% to SF4.51B, Rest of Europe segment increase of 16% to SF11.38B, Rest of Asia segment increase of 13% to SF9.75B, Germany segment increase of 29% to SF4.29B.

Equity composition

3 April 2001, 100 for 1 stock split.

Industry: Pharmaceuticals (NEC)

Grenzacherstrasse 124
BASEL
BASEL-STADT 4058
CH

People also watch

XRP/USD

2.09 Price
-0.720% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01040

Gold

3,327.76 Price
-0.470% 1D Chg, %
Long position overnight fee -0.0169%
Short position overnight fee 0.0087%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

18,303.00 Price
+0.350% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

1,590.31 Price
-1.860% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 720,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading